Discussion  by unknown
JOURNAL OF VASCULAR SURGERY
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tion with critical limb ischemia. Although PTA seemed to
preserve the ability to walk and maintain independence, it did
not seem to improve overall quality-of-life. In other data
published from our institution, the postoperative functional
outcome was often predetermined by the functional status of
the patient at presentation.17 Elderly patients with preopera-
tive ambulatory impairment, dementia, and end-stage renal
disease often achieved very little improvement in their func-
tional performance after objectively successful revasculariza-
tion, regardless of whether the treatment was PTA or open
bypass.On the basis of this experience, it has been our opinion
that we overtreat some patients with critical limb ischemia. If
one were to take a skeptical perspective, the data in this report
show that PTA resulted in amputation-free survival in only
half the cases and provided no improvement in patient health
self-assessment. These outcomes are far from an endorsement
of PTA for the treatment of patients with critical limb isch-
emia. All things considered, the aggregate findings of this
report have done little to change our original opinion.Clearly,
more prospective research in this area is needed to determine
which patients will derive a functional benefit from interven-
tion and which will not.
In summary, technological advancements in the percuta-
neous treatment of PAD have enabled proceduralists to suc-
cessfully treat more complex arterial lesions. Despite docu-
mented limitations in the technical parameter of arterial
patency, excellent functional outcomes with good quality-of-
life assessment are attainablewithPTA.This is particularly true
in patients with claudication. On the grounds of improving
functionality, our findings support a growing body of litera-
ture advocating a more aggressive percutaneous interven-
tional approach to patients with vasculogenic claudication.
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Dr. Robinson: This analysis involves a subgroup of 84 pa-
tients from a previous study who underwent angioplasty forand quality of life was assessed using the SF 36. Patients generally
do well, keep their limbs, remain independent and ambulatory,
have an improved quality of life, and are generally happy. Impor-
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 2 Kalbaugh et al 303tantly, there were no amputations among the 78 limbs treated for
claudication, and a statistically significant improvement in SF-36
measures in all physical function categories. Consequently, the
authors suggest a more liberal use of PTA interventions for patients
with claudication.
However, others have had difficulty showing improvement in
SF-36 scores among vascular patients with any intervention. And
still other survey-tools appear more discriminating in detecting
levels of ischemia and degrees of patient improvement. So for a
sicker patient with more severe disease, even a limited outcome
may be positive and just being able to stand to transfer on one leg
may make a difference. My first question for the authors is about
the limitations of the SF-36 versus more disease-specific question-
naires: Is the SF-36 specific enough and the right “tool” to use to
measure outcomes?
Secondly, one year follow-up gives us little more than a
‘snapshot’, and there is no comparative group. Furthermore, exer-
cise and best medical therapy can measurably improve walking
distance and quality of life for many claudicants. Could you clarify
if all claudicants were relegated to an intervention, or whether
outcomes exist for comparable groups receiving best medical man-
agement alone? Is medical management for claudication passé and
should be abandoned?
Many authors, including our group, have used alternative
methods of assessing patient outcomes to accomplish even better
understanding of “cost-effective” therapy using Markov modeling
to calculate Quality-Adjusted Life Years (QALYs). This would
seem to be ideally suited to the authors’ population. Could the
authors comment and would they consider the application of such
an analysis in a future report?
One last comment. Rapidly developing technology not widely
available when this study was initiated proliferates and nearly
outruns our ability to acquire and analyze meaningful data. None-
theless, modern and sophisticated assessment must include both
delineation of patient function and an analysis of outcomes. I
congratulate the authors on these important efforts and look
forward to their future contributions.
Dr. Tayor: Thanks very much for those comments and ques-
tions. The SF-36 form is an outcomes tool. It is not a perfect tool.
It is one that has become used more widespread than many others,
and I think it is—one needs to caution trying to pick out an
outcomes assessment tool that is tailor made to your patient
population in order to more or less achieve the results that you
wanted to achieve.
In terms of answering that question with theMarkhoff model,
our goal in all of this was to try to keep it very simple. We are
basically blue collar practicing surgeons that have an interest in
trying to figure out what works and what doesn’t work. I mean can
the patient still walk at the end of the procedure and a year later, is
the patient in a nursing home, can the patient stand to dress. Theseto me are things that we as vascular surgeons can understand and
adapt for our patients more so than even a Markhoff model, but I
don’t dispel that we would not have an ideal population for this.
I think the question regarding the medical management of
claudication is intriguing. Be mindful that the LEGS trial, all of
these patients basically hadmedical management first and they only
were enrolled in the LEGS trial after we decided that medical
management was no longer an option and you had made the
decision that you were going to treat this patient with some type of
intervention and selected the treatment for you. All of these
patients had failed medical management before they came to the
trial. The cold hard truth about medical management is—and we
pointed out in the literature—if you really take a pessimistic view of
medical management of claudication, there are multiple studies
that show from the addiction literature that only about a third of
patients that smoke, even though they have a life-threatening
illness, are going to quit smoking. There are studies from Europe
that show that functionality and just patient obstinate alone will
keep people from entering an exercise program in as many as
two-thirds of cases, so if you are a real pessimist you can say that our
best expectation of treating people with medical management is
going to be about a third of patients. Again, that is a very pessimis-
tic view. I’m not advocating that you don’t try, because I think it is
probably the right thing to do but I believe that the things that we
measure from the perspective of claudication is probably no differ-
ent than maybe—and again my opinion—somebody that is having
a knee replacement for an arthritis. These are old people that
basically have bad joints and they can’t walk and they have tried
everything they can do in terms of—is it that much different than
if you are going to treat an SFA angioplasty? It’s clearly a different
disease than what we see with limb-threatening ischemia. I think as
a followup and sort of as a whole digested, to digest everything we
have heard this morning, the striking feature of this study and all
the other studies is critical limb ischemia is a radically different
disease than claudication. It is a radically different disease. It is
manifest in the same disease process in terms of atherosclerosis,
but, as Dan Rush pointed out, critical limb ischemia, in our
conversation this morning, is a systemic disease. We have not
solved—critical limb ischemia is what we talked about on Friday.
We have not solved that problem. That’s a terrible problem, but
claudication, if your mindset is grouped and the claudication
patients are like critical limb ischemia patients, I think you may be
denying some people some treatment that you could possibly help.
Sort of a radical view I think.
It is a moving target. All this is a moving target, the technical
portion of it. In our practice we tend to keep up with the technical
advances in endovascular as well as anybody. I have some really
talented guys, partners, that work with us and work with me and
I’m very blessed to have that, but it is an issue.
